Ragweed-SPIRE Follow-On Study

Circassia Pharmaceuticals

Status: Completed

Conditions: Rhinoconjunctivitis; Ragweed Allergy

Study type: Observational

Funder types: Industry

Identifiers

NCT02396680

TR006A

Details and patient eligibility

About

The purpose of this study is to determine the efficacy of Ragweed-SPIRE 12 months after the initial dose.

Enrollment: 249 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

° Previously randomised into and completed at least 6 of 8 treatment visits in Study TR006

Exclusion criteria

• Subject or Investigator have been informed of treatment received in Study TR006
• Subjects with significant allergy to animal dander
• Any allergen immunotherapy since completing Study TR006 or use of prohibited therapies
• History of recurrent acute sinusitis or chronic sinusitis
• Received treatment with an investigational drug within 4 weeks of Screening
• Unable to understand study requirements or unable to communicate clearly with Investigator

Trial design

249 participants in 1 patient group

TR006 Subjects

Description:

Subjects that have previously been randomised into study TR006